M. Szostak Biography and Net Worth

Director of IDEXX Laboratories

Ms. Szostak had a 31-year career with Fleet/Boston Financial Group (now Bank of America), a diversified financial services company, until her retirement in 2004. She served as Board Chair and Chief Executive Officer of Fleet Bank-Rhode Island from 2001 to 2003, Board Chair, President and Chief Executive Officer of Fleet-Maine from 1991 to 1994, and Corporate Executive Vice President and Chief Human Resources Officer of FleetBoston Financial Group from 1998 to 2004. After her retirement, Ms. Szostak founded Szostak Partners, an executive coaching and human resources consulting firm, and as President of Szostak Partners, she provides strategic advice and counsel to clients. Ms. Szostak has been a director of Tupperware Brands Corporation since 2000. Ms. Szostak previously served on the boards of directors of Dr. Pepper Snapple Group, Inc. from 2008 to 2018, Spherion Corporation from 2005 to 2011 and Belo Corp. from 2004 to 2013. Ms. Szostak holds an undergraduate degree from Colby College, and she has completed several executive education programs at Harvard Business School.

What is M. Anne Szostak's net worth?: The estimated net worth of M. Anne Szostak is at least $519,447.60 as of December 2nd, 2022. Ms. Szostak owns 1,260 shares of IDEXX Laboratories stock worth more than $519,448 as of December 21st. This net worth evaluation does not reflect any other investments that Ms. Szostak may own. Learn More about M. Anne Szostak's net worth.
How do I contact M. Anne Szostak?: The corporate mailing address for Ms. Szostak and other IDEXX Laboratories executives is ONE IDEXX DRIVE, WESTBROOK ME, 04092. IDEXX Laboratories can also be reached via phone at (207) 556-0300 and via email at [email protected]. Learn More on M. Anne Szostak's contact information.
Has M. Anne Szostak been buying or selling shares of IDEXX Laboratories?: M. Anne Szostak has not been actively trading shares of IDEXX Laboratories during the last ninety days. Most recently, M Anne Szostak sold 740 shares of the business's stock in a transaction on Friday, December 2nd. The shares were sold at an average price of $428.55, for a transaction totalling $317,127.00. Following the completion of the sale, the director now directly owns 1,260 shares of the company's stock, valued at $539,973. Learn More on M. Anne Szostak's trading history.
Who are IDEXX Laboratories' active insiders?: IDEXX Laboratories' insider roster includes Jonathan Ayers (Director), Bruce Claflin (Director), George Fennell (SVP), Rebecca Henderson (Director), Nimrata Hunt (EVP), Daniel Junius (Director), Michael Lane (EVP), Jonathan Mazelsky (CEO), Brian Mckeon (CFO), James Polewaczyk (EVP), M. Szostak (Director), Kathy Turner (SVP), Kathy Turner (SVP), Giovani Twigge (SVP), and Sophie Vandebroek (Director). Learn More on IDEXX Laboratories' active insiders.
Are insiders buying or selling shares of IDEXX Laboratories?: During the last year, insiders at the sold shares 5 times. They sold a total of 44,068 shares worth more than $25,124,750.88. The most recent insider tranaction occured on November, 27th when Director Sophie V Vandebroek sold 344 shares worth more than $144,631.36. Insiders at IDEXX Laboratories own 2.1% of the company. Learn More about insider trades at IDEXX Laboratories.
Information on this page was last updated on 11/27/2024.

M. Anne Szostak Insider Trading History at IDEXX Laboratories

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
12/2/2022	Sell	740	$428.55	$317,127.00	1,260
8/6/2021	Sell	3,000	$687.87	$2,063,610.00
2/4/2021	Sell	11,876	$489.71	$5,815,795.96	5,974
5/29/2020	Sell	7,722	$306.91	$2,369,959.02	7,722
11/4/2019	Sell	3,283	$279.37	$917,171.71	584
2/14/2019	Sell	5,906	$208.96	$1,234,117.76	6,490
8/13/2014	Buy	2,000	$127.03	$254,060.00
2/20/2014	Buy	2,000	$126.71	$253,420.00	5,000
11/4/2013	Buy	1,000	$108.24	$108,240.00	3,000

M. Anne Szostak Buying and Selling Activity at IDEXX Laboratories

IDEXX Laboratories Company Overview

IDEXX Laboratories, Inc. develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy. It also provides point-of-care veterinary diagnostic products, including instruments, consumables, and rapid assay test kits; veterinary reference laboratory diagnostic and consulting services; practice management and diagnostic imaging systems and services for veterinarians; and health monitoring, biological materials testing, and laboratory diagnostic instruments, and services for biomedical research community. In addition, the company offers diagnostic and health-monitoring products for livestock, poultry, and dairy; products that test water for various microbiological contaminants; point-of-care electrolytes and blood gas analyzers; in-clinic chemistry, blood and urine chemistry, hematology, immunoassay, urinalysis, and coagulation analyzers; and SNAP rapid assays test kits. Further, it provides Colilert, Colilert-18, and Colisure tests, which detect the presence of total coliforms and E. coli in water; Enterolert, Pseudalert, Filta-Max and Filta-Max xpress, Legiolert, and Quanti-Tray products; and veterinary software and services for independent veterinary clinics and corporate groups. Additionally, the company offers human medical point-of-care products and laboratory diagnostics services. The company markets its products through marketing, customer service, sales, and technical service groups, as well as through independent distributors and other resellers. IDEXX Laboratories, Inc. was incorporated in 1983 and is headquartered in Westbrook, Maine.

Today's Range

Now: $412.26

$404.36

$418.26

50 Day Range

MA: $433.90

$406.92

$478.00

2 Week Range

Now: $412.26

$398.50

$583.39

Volume

1,122,179 shs

Average Volume

516,185 shs

Market Capitalization

$33.76 billion

P/E Ratio

39.76

Dividend Yield

N/A

Beta

1.37

Media Humiliated: Demo of Elon’s Tech Proves They’re Wrong

From Brownstone Research | Ad

Elon Musk believes his new AI product will be worth an incredible $9 trillion. But the mainstream media is not buying it.

Click here to watch this demo and decide for yourself.